JP2023504748A - 抗pd-l1抗体製剤 - Google Patents

抗pd-l1抗体製剤 Download PDF

Info

Publication number
JP2023504748A
JP2023504748A JP2022534224A JP2022534224A JP2023504748A JP 2023504748 A JP2023504748 A JP 2023504748A JP 2022534224 A JP2022534224 A JP 2022534224A JP 2022534224 A JP2022534224 A JP 2022534224A JP 2023504748 A JP2023504748 A JP 2023504748A
Authority
JP
Japan
Prior art keywords
liquid pharmaceutical
pharmaceutical formulation
concentration
formulation
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022534224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504748A5 (cg-RX-API-DMAC7.html
Inventor
アダ ヒュイ,
ジュディス チュー-シモニ,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2023504748A publication Critical patent/JP2023504748A/ja
Publication of JP2023504748A5 publication Critical patent/JP2023504748A5/ja
Priority to JP2025152037A priority Critical patent/JP2026009902A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022534224A 2019-12-09 2020-12-07 抗pd-l1抗体製剤 Withdrawn JP2023504748A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025152037A JP2026009902A (ja) 2019-12-09 2025-09-12 抗pd-l1抗体製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945730P 2019-12-09 2019-12-09
US62/945,730 2019-12-09
PCT/US2020/063620 WO2021118930A2 (en) 2019-12-09 2020-12-07 Anti-pd-l1 antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025152037A Division JP2026009902A (ja) 2019-12-09 2025-09-12 抗pd-l1抗体製剤

Publications (2)

Publication Number Publication Date
JP2023504748A true JP2023504748A (ja) 2023-02-06
JP2023504748A5 JP2023504748A5 (cg-RX-API-DMAC7.html) 2023-12-14

Family

ID=74206149

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022534224A Withdrawn JP2023504748A (ja) 2019-12-09 2020-12-07 抗pd-l1抗体製剤
JP2025152037A Pending JP2026009902A (ja) 2019-12-09 2025-09-12 抗pd-l1抗体製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025152037A Pending JP2026009902A (ja) 2019-12-09 2025-09-12 抗pd-l1抗体製剤

Country Status (15)

Country Link
US (1) US20230039268A1 (cg-RX-API-DMAC7.html)
EP (1) EP4073120A2 (cg-RX-API-DMAC7.html)
JP (2) JP2023504748A (cg-RX-API-DMAC7.html)
KR (1) KR20220113414A (cg-RX-API-DMAC7.html)
CN (1) CN114787191A (cg-RX-API-DMAC7.html)
AU (1) AU2020399619A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022011228A2 (cg-RX-API-DMAC7.html)
CA (1) CA3158987A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022001486A1 (cg-RX-API-DMAC7.html)
CR (1) CR20220322A (cg-RX-API-DMAC7.html)
IL (1) IL293580A (cg-RX-API-DMAC7.html)
MX (1) MX2022006784A (cg-RX-API-DMAC7.html)
PE (1) PE20221281A1 (cg-RX-API-DMAC7.html)
TW (1) TWI886185B (cg-RX-API-DMAC7.html)
WO (1) WO2021118930A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
MA54089A (fr) 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
MX2024007749A (es) 2021-12-22 2024-07-01 Genentech Inc Formulaciones clinicas de anticuerpos anti-tigit.
WO2024126750A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Methods for treating cancer
JP2026508415A (ja) * 2023-03-08 2026-03-10 イムノバント サイエンシズ ゲーエムベーハー ポリソルベート賦形剤を含む高濃度タンパク質製剤およびその製造方法
WO2025085404A1 (en) 2023-10-16 2025-04-24 Genentech, Inc. Diagnostic and therapeutic methods for treating lung cancer
WO2026158433A1 (zh) * 2025-01-24 2026-07-30 江苏恒瑞医药股份有限公司 一种包含抗pd-l1抗体的药物组合物及其医药用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504540A (ja) * 2009-09-11 2013-02-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 高度に濃縮された薬学的製剤
JP2016533335A (ja) * 2013-09-27 2016-10-27 ジェネンテック, インコーポレイテッド 抗pdl1抗体製剤
WO2018136412A2 (en) * 2017-01-17 2018-07-26 Genentech, Inc. Subcutaneous her2 antibody formulations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504540A (ja) * 2009-09-11 2013-02-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 高度に濃縮された薬学的製剤
JP2016533335A (ja) * 2013-09-27 2016-10-27 ジェネンテック, インコーポレイテッド 抗pdl1抗体製剤
WO2018136412A2 (en) * 2017-01-17 2018-07-26 Genentech, Inc. Subcutaneous her2 antibody formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GEBURTSHILFE FRAUENHEILKD, vol. 74, no. 4, JPN6024047878, 2014, pages 343 - 349, ISSN: 0005591937 *

Also Published As

Publication number Publication date
PE20221281A1 (es) 2022-09-05
CL2023001140A1 (es) 2023-10-06
CL2022001486A1 (es) 2023-01-20
IL293580A (en) 2022-08-01
JP2026009902A (ja) 2026-01-21
CR20220322A (es) 2022-07-28
AU2020399619A1 (en) 2022-06-09
KR20220113414A (ko) 2022-08-12
TWI886185B (zh) 2025-06-11
BR112022011228A2 (pt) 2022-10-11
US20230039268A1 (en) 2023-02-09
MX2022006784A (es) 2022-07-11
CA3158987A1 (en) 2021-06-17
CN114787191A (zh) 2022-07-22
WO2021118930A2 (en) 2021-06-17
EP4073120A2 (en) 2022-10-19
TW202128223A (zh) 2021-08-01
WO2021118930A3 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
TWI886185B (zh) 抗pd-l1抗體調配物
JP6769687B1 (ja) 皮下her2抗体製剤
AU2020203267B2 (en) Anti-PDL1 antibody formulations
ES2413090T5 (es) Formulación subcutánea de anticuerpo anti-HER2
TWI515021B (zh) 包含抗-cd20抗體之高濃縮醫藥調配物及其用途
RU2855065C1 (ru) Составы на основе антитела к pd-l1
HK40068833A (en) Anti-pd-l1 antibody formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231206

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250513

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250917